These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 534675)

  • 21. [The anticoagulant activity of the plasma ultrafiltrate as a possible criterion of uremic poisoning].
    Sukhanov VA; Chuzhinov SV; Koriakov IO; Zlokazov VB
    Ter Arkh; 1991; 63(6):68-71. PubMed ID: 1948752
    [No Abstract]   [Full Text] [Related]  

  • 22. Middle molecules in hepatic coma and uremia.
    Chang TM; Lister C
    Artif Organs; 1981; 4 Suppl():169-72. PubMed ID: 7295086
    [No Abstract]   [Full Text] [Related]  

  • 23. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance.
    Gugliucci A; Mehlhaff K; Kinugasa E; Ogata H; Hermo R; Schulze J; Kimura S
    Clin Chim Acta; 2007 Feb; 377(1-2):213-20. PubMed ID: 17118352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure.
    Mohora M; Mircescu G; Cîrjan C; Mihăilescu I; Gîrneaţă L; Ursea N; Dinu V
    Rom J Intern Med; 1995; 33(3-4):237-42. PubMed ID: 8646196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of uremic middle molecules on in vitro stimulated lymphocytes and interleukin-2 production.
    Severini G; Diana L; Di Giovannandrea R; Sagliaschi G
    ASAIO J; 1996; 42(1):64-7. PubMed ID: 8808461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Plasma and intra-erythrocytic concentrations of copper and zinc in uremic patients treated by periodic hemodialysis].
    Agenet C; Brugère CC; Reynier JP
    Ann Biol Clin (Paris); 1989; 47(8):493-6. PubMed ID: 2690680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of transepithelial sodium transport in the frog skin by a low molecular weight fraction of uremic serum.
    Bourgoignie J; Klahr S; Bricker NS
    J Clin Invest; 1971 Feb; 50(2):303-11. PubMed ID: 5540168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toxicity of middle molecules: clinical evaluation using a selective filtration artificial kidney.
    Jörstad S; Smeby LC; Wideröe TE
    Artif Organs; 1981; 4 Suppl():98-103. PubMed ID: 7295103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of phagocytosis by a middle molecular fraction from ultrafiltrate.
    Ringoir SM; van Landschoot N; de Smet R
    Clin Nephrol; 1980 Mar; 13(3):109-12. PubMed ID: 7379359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anemia of chronic renal failure: erythropoiesis and serum inhibitor(s) of erythroid progenitor cells in uremia].
    Urushiyama M; Moriyama Y
    Rinsho Ketsueki; 1985 May; 26(5):668-73. PubMed ID: 4057581
    [No Abstract]   [Full Text] [Related]  

  • 31. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R; Emond C; Claret G; Branger B; Mion H; Mion C
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anemia in patients with chronic kidney failure undergoing systematic hemodialysis treatment].
    Landar' VA; Sarycheva TG; Shemetov VD; Kozinets GI
    Urol Nefrol (Mosk); 1989; (1):54-5. PubMed ID: 2718284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative study of acetate and bicarbonate hemodialysis in children with chronic uremia].
    Dobos E; Túri S; Sztriha L
    Orv Hetil; 1991 Aug; 132(32):1749-54. PubMed ID: 1908071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Middle molecules in uremic serum, urine and dialysis fluid.
    Migone L; Dall'taglio P; Buzio C
    Clin Nephrol; 1975; 3(3):82-93. PubMed ID: 1139803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H; Bergström J; Fürst P; Johnson C; Yahiel V
    Artif Organs; 1981; 4 Suppl():137-42. PubMed ID: 7295080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoiesis activity, iron availability and reticulocyte hemoglobinization during treatment with hemodialysis and in subjects with uremia.
    Schoorl M; Schoorl M; Nubé MJ; Bartels PC
    Clin Lab; 2006; 52(11-12):621-9. PubMed ID: 17175894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum and ultradiafiltrate middle molecules in hemodialysed patients.
    Bozek P; Erben J; Zahradnik J; Dzúrik R
    Int Urol Nephrol; 1979; 11(3):223-8. PubMed ID: 500299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Can the concentration of middle molecular substances in plasma contribute to the assessment of the adequacy of regular dialysis therapy?].
    Válek A; Spustová V; Lopot F; Erben J; Dzúrik R
    Cas Lek Cesk; 1984 May; 123(20):599-604. PubMed ID: 6467309
    [No Abstract]   [Full Text] [Related]  

  • 39. The binding of chloramphenicol to serum proteins in patients with chronic renal insufficiency.
    Grafnetterová J; Vodrázka Z; Jandová D; Schück O; Tomásek R; Lachmanová J
    Clin Nephrol; 1976 Oct; 6(4):448-50. PubMed ID: 975643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Study of carbohydrate material isolated from ultrafiltrates in patients with chronic renal failure.
    Le Moël G; Strecker G; Troupel S; Dupuy CA; Galli A; Agneray J
    Biomed Pharmacother; 1983; 37(2):80-5. PubMed ID: 6616034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.